Grown Rogue International (GRUSF) Income from Continuing Operations (2018 - 2026)
Grown Rogue International (GRUSF) recorded quarterly Income from Continuing Operations of 2213391.0 in Q1 2026, up 42.78% quarter-over-quarter from 3868338.0 in Q4 2025, and down 397.95% on a YoY basis from 742870.0 in Q1 2025.
Grown Rogue International (GRUSF) Income from Continuing Operations (2018 - 2026) Analysis & Trends
Grown Rogue International's Income from Continuing Operations history runs 9 years deep, the most recent figure standing at 2213391.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 397.95% year-over-year to 2213391.0; the TTM figure through Mar 2026 stood at 837085640026.28 (up 152949093.24% YoY), while the FY2025 annual figure was 2621662.0, up 158.0% from the prior year.
- Income from Continuing Operations was 2213391.0 for Q1 2026 at Grown Rogue International, up from 3868338.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 1709983000000.0 in Q3 2025 to a low of 872891278244.72 in Q2 2025.
- Historically, Income from Continuing Operations has averaged 55806229607.23 across 5 years, with a median of 742870.0 in 2025.
- Biggest YoY gain for Income from Continuing Operations was 238831302.76% in 2025; the steepest drop was 15476993.38% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 601273.0 in 2022, then rose by 11.83% to 672427.0 in 2023, then slumped by 1074.31% to 6551517.0 in 2024, then surged by 40.96% to 3868338.0 in 2025, then surged by 42.78% to 2213391.0 in 2026.
- The last three Income from Continuing Operations figures came in at 2213391.0 (Q1 2026), 3868338.0 (Q4 2025), and 1709983000000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 370.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 601.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 274.90 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 21.05 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 197.90 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -66.53 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -92.12 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 118.42 Mn |
| 10 | Grown Rogue International | - | - | 3.96 Mn | -2.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.21 Mn |
| Dec 31, 2025 | -3.87 Mn |
| Sep 30, 2025 | 1,709.98 Bn |
| Jun 30, 2025 | -872.89 Bn |
| Mar 31, 2025 | 742,870.00 |
| Dec 31, 2024 | -6.55 Mn |
| Sep 30, 2024 | 715,979.13 |
| Jun 30, 2024 | 5.64 Mn |
| Mar 31, 2024 | 1.12 Mn |
| Dec 31, 2023 | 672,427.00 |
| Oct 31, 2023 | 1.65 Mn |
| Jul 31, 2023 | 1.55 Mn |
| Apr 30, 2023 | 920,853.00 |
| Jan 31, 2023 | 746,309.00 |
| Jan 31, 2022 | 601,273.00 |
| Oct 31, 2021 | 1.62 Mn |
| Jul 31, 2021 | 764,360.00 |
| Apr 30, 2021 | -586,589.00 |
| Jan 31, 2021 | -978,539.00 |
| Oct 31, 2020 | -610,383.00 |